{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:04:45Z","timestamp":1786982685081,"version":"build-2736575974"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CEN Case Rep"],"DOI":"10.1007\/s13730-026-01118-1","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T02:14:24Z","timestamp":1777428864000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Single-dose rituximab as induction therapy in adult IgA vasculitis with rapidly progressive glomerulonephritis: a case report with peripheral blood CD19\u207a B-cell monitoring"],"prefix":"10.1007","volume":"15","author":[{"given":"Naoko","family":"Kyoda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6427-6733","authenticated-orcid":false,"given":"Rika","family":"Ago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Masuzawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Yanamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaho","family":"Aizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takao","family":"Masaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"issue":"5","key":"1118_CR1","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10157-013-0869-6","volume":"17","author":"JC Jennette","year":"2013","unstructured":"Jennette JC. Overview of the 2012 revised international Chapel Hill Consensus conference nomenclature of vasculitides. Clin Exp Nephrol. 2013;17(5):603\u20136. https:\/\/doi.org\/10.1007\/s10157-013-0869-6.","journal-title":"Clin Exp Nephrol"},{"issue":"8","key":"1118_CR2","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1093\/ckj\/sfaa251","volume":"14","author":"E Van de Perre","year":"2021","unstructured":"Van de Perre E, Jones RB, Jayne DRW. IgA vasculitis (Henoch-Sch\u00f6nlein purpura): refractory and relapsing disease course in the adult population. Clin Kidney J. 2021;14(8):1953\u201360. https:\/\/doi.org\/10.1093\/ckj\/sfaa251.","journal-title":"Clin Kidney J"},{"issue":"1","key":"1118_CR3","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1093\/ckj\/sfw106","volume":"10","author":"S Lundberg","year":"2017","unstructured":"Lundberg S, Westergren E, Smolander J, Bruchfeld A. B cell depleting therapy with rituximab or ofatumumab in immunoglobulin A nephropathy or vasculitis with nephritis. Clin Kidney J. 2017;10(1):20\u20136. https:\/\/doi.org\/10.1093\/ckj\/sfw106.","journal-title":"Clin Kidney J"},{"issue":"1","key":"1118_CR4","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1002\/art.40339","volume":"70","author":"F Maritati","year":"2018","unstructured":"Maritati F, Fenoglio R, Pillebout E, Emmi G, Urban ML, Rocco R, Nicastro M, Incerti M, Goldoni M, Trivioli G, Silvestri E, Mohammad AJ, Jayne D, Eriksson P, Segelmark M, Novikov P, Harris H, Roccatello D, Vaglio A. Rituximab for the treatment of adult-onset IgA vasculitis (Henoch-Sch\u00f6nlein). Arthritis Rheumatol. 2018;70(1):109\u201314. https:\/\/doi.org\/10.1002\/art.40339.","journal-title":"Arthritis Rheumatol"},{"issue":"Suppl 124","key":"1118_CR5","first-page":"S195","volume":"38","author":"R Fenoglio","year":"2020","unstructured":"Fenoglio R, Sciascia S, Naretto C, De Simone E, Del Vecchio G, Ferro M, Quattrocchio G, Roccatello D. Rituximab in severe immunoglobulin-A vasculitis (Henoch-Sch\u00f6nlein) with aggressive nephritis. Clin Exp Rheumatol. 2020;38(Suppl 124):S195\u2013200.","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"1118_CR6","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1002\/art.1780400513","volume":"40","author":"R Blanco","year":"1997","unstructured":"Blanco R, Mart\u00ednez-Taboada VM, Rodr\u00edguez-Valverde V, Garc\u00eda-Fuentes M, Gonz\u00e1lez-Gay MA. Henoch-Schonlein purpura in adulthood and childhood: two different expressions of the same syndrome. Arthritis Rheum. 1997;40(5):859\u201364. https:\/\/doi.org\/10.1002\/art.1780400513.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"1118_CR7","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1053\/j.ajkd.2006.02.178","volume":"47","author":"R Coppo","year":"2006","unstructured":"Coppo R, Andrulli S, Amore A, Gianoglio B, Conti G, Peruzzi L, Locatelli F, Cagnoli L. Predictors of outcome in Henoch-Sch\u00f6nlein nephritis in children and adults. Am J Kidney Dis. 2006;47(6):993\u20131003. https:\/\/doi.org\/10.1053\/j.ajkd.2006.02.178.","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"1118_CR8","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.semarthrit.2012.07.004","volume":"42","author":"S Rajagopala","year":"2013","unstructured":"Rajagopala S, Shobha V, Devaraj U, D\u2019Souza G, Garg I. Pulmonary hemorrhage in Henoch-Sch\u00f6nlein purpura: case report and systematic review of the English literature. Semin Arthritis Rheum. 2013;42(4):391\u2013400. https:\/\/doi.org\/10.1016\/j.semarthrit.2012.07.004.","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"1118_CR9","doi-asserted-by":"publisher","first-page":"2289614","DOI":"10.1080\/07853890.2023.2289614","volume":"55","author":"F Qi","year":"2023","unstructured":"Qi F, Hao J, Wei W. Impact of different ANCA serotypes on the long-term outcome of ANCA-associated vasculitis patients. Ann Med. 2023;55(2):2289614. https:\/\/doi.org\/10.1080\/07853890.2023.2289614.","journal-title":"Ann Med"},{"key":"1118_CR10","doi-asserted-by":"publisher","first-page":"iii74","DOI":"10.1093\/rheumatology\/kez618","volume":"59","author":"R Smith","year":"2020","unstructured":"Smith R. Complications of therapy for ANCA-associated vasculitis. Rheumatology (Oxford). 2020;59:iii74\u20138. https:\/\/doi.org\/10.1093\/rheumatology\/kez618.","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"1118_CR11","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1016\/j.autrev.2017.10.009","volume":"16","author":"MH Heineke","year":"2017","unstructured":"Heineke MH, Ballering AV, Jamin A, Ben Mkaddem S, Monteiro RC, Van Egmond M. New insights in the pathogenesis of immunoglobulin A vasculitis (Henoch-Sch\u00f6nlein purpura). Autoimmun Rev. 2017;16(12):1246\u201353. https:\/\/doi.org\/10.1016\/j.autrev.2017.10.009.","journal-title":"Autoimmun Rev"},{"issue":"4","key":"1118_CR12","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.kint.2025.04.003","volume":"108","author":"J Floege","year":"2025","unstructured":"Floege J, Barratt J, Cook HT, Noronha IL, Reich HN, Suzuki Y, Tang SCW, Trimarchi H, Balk EM, Gordon CE, Adam GP, Tonelli MA, Earley A, Rovin BH. Executive summary of the KDIGO 2025 clinical practice guideline for the management of immunoglobulin a nephropathy (IgAN) and immunoglobulin a vasculitis (IgAV). Kidney Int. 2025;108(4):548\u201354. https:\/\/doi.org\/10.1016\/j.kint.2025.04.003.","journal-title":"Kidney Int"},{"issue":"Suppl 1","key":"1118_CR13","doi-asserted-by":"publisher","first-page":"S44","DOI":"10.3346\/jkms.2009.24.S1.S44","volume":"24","author":"SM Kim","year":"2009","unstructured":"Kim SM, Moon KC, Oh KH, Joo KW, Kim YS, Ahn C, Han JS, Kim S. Clinicopathologic characteristics of IgA nephropathy with steroid-responsive nephrotic syndrome. J Korean Med Sci. 2009;24(Suppl 1):S44\u20139. https:\/\/doi.org\/10.3346\/jkms.2009.24.S1.S44.","journal-title":"J Korean Med Sci"},{"key":"1118_CR14","doi-asserted-by":"publisher","first-page":"1128393","DOI":"10.3389\/fmed.2023.1128393","volume":"10","author":"H Zhang","year":"2023","unstructured":"Zhang H, Deng Z, Wang Y. Molecular insight in intrarenal inflammation affecting four main types of cells in nephrons in IgA nephropathy. Front Med (Lausanne). 2023;10:1128393. https:\/\/doi.org\/10.3389\/fmed.2023.1128393.","journal-title":"Front Med (Lausanne)"},{"issue":"6","key":"1118_CR15","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/j.kint.2024.03.011","volume":"105","author":"SS Bellur","year":"2024","unstructured":"Bellur SS, Troyanov S, Vorobyeva O, Coppo R, Roberts ISD. Validation in IgA Nephropathy study group. Evidence from the large VALIGA cohort validates the subclassification of focal segmental glomerulosclerosis in IgA nephropathy. Kidney Int. 2024;105(6):1279\u201390. https:\/\/doi.org\/10.1016\/j.kint.2024.03.011.","journal-title":"Kidney Int"},{"issue":"4","key":"1118_CR16","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1681\/ASN.2016060640","volume":"28","author":"RA Lafayette","year":"2017","unstructured":"Lafayette RA, Canetta PA, Rovin BH, Appel GB, Novak J, Nath KA, Sethi S, Tumlin JA, Mehta K, Hogan M, Erickson S, Julian BA, Leung N, Enders FT, Brown R, Knoppova B, Hall S, Fervenza FC. A randomized, controlled trial of rituximab in IgA nephropathy with proteinuria and renal dysfunction. J Am Soc Nephrol. 2017;28(4):1306\u201313. https:\/\/doi.org\/10.1681\/ASN.2016060640.","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"1118_CR17","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1681\/ASN.2017040367","volume":"29","author":"E Schrezenmeier","year":"2018","unstructured":"Schrezenmeier E, Jayne D, D\u00f6rner T. Targeting B cells and plasma cells in glomerular diseases: translational perspectives. J Am Soc Nephrol. 2018;29(3):741\u201358. https:\/\/doi.org\/10.1681\/ASN.2017040367.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"1118_CR18","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s12882-023-03198-y","volume":"24","author":"S El\u00edasd\u00f3ttir","year":"2023","unstructured":"El\u00edasd\u00f3ttir S, Khramova A, Saeed A, Guron G, Boi R, M\u00f6lne J, Ebefors K, Nystr\u00f6m J. Serum levels of galactose-deficient IgA are elevated in patients with IgA nephropathy but do not correlate to disease activity or progression. BMC Nephrol. 2023;24(1):160. https:\/\/doi.org\/10.1186\/s12882-023-03198-y.","journal-title":"BMC Nephrol"},{"issue":"7","key":"1118_CR19","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1038\/ki.2012.197","volume":"82","author":"N Zhao","year":"2012","unstructured":"Zhao N, Hou P, Lv J, Moldoveanu Z, Li Y, Kiryluk K, Gharavi AG, Novak J, Zhang H. The level of galactose-deficient IgA1 in the sera of patients with IgA nephropathy is associated with disease progression. Kidney Int. 2012;82(7):790\u20136. https:\/\/doi.org\/10.1038\/ki.2012.197.","journal-title":"Kidney Int"},{"issue":"10","key":"1118_CR20","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.3390\/jcm11102810","volume":"11","author":"D Maixnerova","year":"2022","unstructured":"Maixnerova D, Zhang H, Rizk DV, El Mehdi D, Tesar V. New treatment strategies for IgA nephropathy: targeting plasma cells as the main source of pathogenic antibodies. J Clin Med. 2022;11(10):2810. https:\/\/doi.org\/10.3390\/jcm11102810.","journal-title":"J Clin Med"},{"issue":"10","key":"1118_CR21","doi-asserted-by":"publisher","first-page":"e0163085","DOI":"10.1371\/journal.pone.0163085","volume":"11","author":"A Kondo","year":"2016","unstructured":"Kondo A, Takahashi K, Mizuno T, Kato A, Hirano D, Yamamoto N, Hayashi H, Koide S, Takahashi H, Hasegawa M, Hiki Y, Yoshida S, Miura K, Yuzawa Y. The level of IgA antibodies to endothelial cells correlates with histological evidence of disease activity in patients with lupus nephritis. PLoS ONE. 2016;11(10):e0163085. https:\/\/doi.org\/10.1371\/journal.pone.0163085.","journal-title":"PLoS ONE"},{"issue":"6","key":"1118_CR22","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.anai.2023.01.018","volume":"130","author":"TS Athni","year":"2023","unstructured":"Athni TS, Barmettler S. Hypogammaglobulinemia, late-onset neutropenia, and infections following rituximab. Ann Allergy Asthma Immunol. 2023;130(6):699\u2013712. https:\/\/doi.org\/10.1016\/j.anai.2023.01.018.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"8","key":"1118_CR23","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1111\/imj.13136","volume":"46","author":"P Kotagiri","year":"2016","unstructured":"Kotagiri P, Martin A, Hughes P, Becker G, Nicholls K. Single-dose rituximab in refractory lupus nephritis. Intern Med J. 2016;46(8):899\u2013901. https:\/\/doi.org\/10.1111\/imj.13136.","journal-title":"Intern Med J"},{"issue":"5","key":"1118_CR24","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1093\/ndt\/gfs515","volume":"28","author":"T Takei","year":"2013","unstructured":"Takei T, Itabashi M, Moriyama T, Kojima C, Shiohira S, Shimizu A, Tsuruta Y, Ochi A, Amemiya N, Mochizuki T, Uchida K, Tsuchiya K, Nitta K. Effect of single-dose rituximab on steroid-dependent minimal-change nephrotic syndrome in adults. Nephrol Dial Transpl. 2013;28(5):1225\u201332. https:\/\/doi.org\/10.1093\/ndt\/gfs515.","journal-title":"Nephrol Dial Transpl"},{"issue":"3","key":"1118_CR25","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1002\/art.30152","volume":"63","author":"EM Vital","year":"2011","unstructured":"Vital EM, Rawstron AC, Dass S, Henshaw K, Madden J, Emery P, McGonagle D. Reduced-dose rituximab in rheumatoid arthritis: efficacy depends on degree of B cell depletion. Arthritis Rheum. 2011;63(3):603\u20138. https:\/\/doi.org\/10.1002\/art.30152.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"1118_CR26","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13075-017-1306-0","volume":"19","author":"J Thiel","year":"2017","unstructured":"Thiel J, Rizzi M, Engesser M, Dufner AK, Troilo A, Lorenzetti R, Voll RE, Venhoff N. B cell repopulation kinetics after rituximab treatment in ANCA-associated vasculitides compared to rheumatoid arthritis, and connective tissue diseases: a longitudinal observational study on 120 patients. Arthritis Res Ther. 2017;19(1):101. https:\/\/doi.org\/10.1186\/s13075-017-1306-0.","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"1118_CR27","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1002\/art.34359","volume":"64","author":"BH Rovin","year":"2012","unstructured":"Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, Maciuca R, Zhang D, Garg JP, Brunetta P, Appel G, LUNAR Investigator Group. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study. Arthritis Rheum. 2012;64(4):1215\u201326. https:\/\/doi.org\/10.1002\/art.34359.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"1118_CR28","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/art.27233","volume":"62","author":"JT Merrill","year":"2010","unstructured":"Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, Utset TO, Gordon C, Isenberg DA, Hsieh HJ, Zhang D, Brunetta PG. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010;62(1):222\u201333. https:\/\/doi.org\/10.1002\/art.27233.","journal-title":"Arthritis Rheum"},{"issue":"10","key":"1118_CR29","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.1111\/j.1600-6143.2006.01497.x","volume":"6","author":"H Genberg","year":"2006","unstructured":"Genberg H, Hansson A, Wernerson A, Wennberg L, Tyd\u00e9n G. Pharmacodynamics of rituximab in kidney allotransplantation. Am J Transpl. 2006;6(10):2418\u201328. https:\/\/doi.org\/10.1111\/j.1600-6143.2006.01497.x.","journal-title":"Am J Transpl"},{"issue":"10","key":"1118_CR30","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.2215\/CJN.01070118","volume":"13","author":"LM Gomez Mendez","year":"2018","unstructured":"Gomez Mendez LM, Cascino MD, Garg J, Katsumoto TR, Brakeman P, Dall\u2019Era M, Looney RJ, Rovin B, Dragone L, Brunetta P. Peripheral blood B cell depletion after rituximab and complete response in lupus nephritis. Clin J Am Soc Nephrol. 2018;13(10):1502\u201309. https:\/\/doi.org\/10.2215\/CJN.01070118.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"1118_CR31","doi-asserted-by":"publisher","first-page":"e463","DOI":"10.1212\/NXI.0000000000000463","volume":"5","author":"E Ellwardt","year":"2018","unstructured":"Ellwardt E, Ellwardt L, Bittner S, Zipp F. Monitoring B-cell repopulation after depletion therapy in neurologic patients. Neurol Neuroimmunol Neuroinflamm. 2018;5(4):e463. https:\/\/doi.org\/10.1212\/NXI.0000000000000463.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"1","key":"1118_CR32","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13075-024-03297-7","volume":"26","author":"S Pollastro","year":"2024","unstructured":"Pollastro S, Musters A, Balzaretti G, Niewold I, van Schaik B, H\u00e4ssler S, Verhoef CM, Pallardy M, van Kampen A, Mariette X, de Vries N, ABIRISK Consortium. Sensitive B-cell receptor repertoire analysis shows repopulation correlates with clinical response to rituximab in rheumatoid arthritis. Arthritis Res Ther. 2024;26(1):70. https:\/\/doi.org\/10.1186\/s13075-024-03297-7.","journal-title":"Arthritis Res Ther"},{"key":"1118_CR33","doi-asserted-by":"publisher","unstructured":"Berkani N, Joly P, Golinski ML, Colliou N, Lim A, Larbi A, Riou G, Caillot F, Bernard P, Bedane C, Delaporte E, Chaby G, Dompmartin A, Hertl M, Calbo S, Musette P. B-cell depletion induces a shift in self antigen specific B-cell repertoire and cytokine pattern in patients with bullous pemphigoid. Sci Rep. 2019; 9(1):3525. https:\/\/doi.org\/10.1038\/s41598-019-40203-7. Erratum in: Sci Rep. 2019; 9(1):18991. https:\/\/doi.org\/10.1038\/s41598-019-54421-6.","DOI":"10.1038\/s41598-019-40203-7"}],"container-title":["CEN Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-026-01118-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13730-026-01118-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-026-01118-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T02:14:26Z","timestamp":1777428866000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13730-026-01118-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":33,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["1118"],"URL":"https:\/\/doi.org\/10.1007\/s13730-026-01118-1","relation":{},"ISSN":["2192-4449"],"issn-type":[{"value":"2192-4449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,29]]},"assertion":[{"value":"6 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have declared that no conflict of interest exists.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The off-label use of RTX was approved by the Ethics Committee of Miyoshi Central Hospital (approval number: 040114-1).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor of this journal.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"78"}}